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Detection of myxovirus resistance protein A 
in lichen planus lesions and its relationship  
to hepatitis C virus
Type I interferons (IFNs) stimulate the production of sev-
eral IFN-induced proteins including myxovirus resistance 
protein A (MxA protein). The association of lichen planus 
(LP) and chronic hepatitis C is well established, with vari-
able prevalence rates among different populations. Many 
authors have considered hepatitis C virus (HCV) as a pos-
sible antigen for inducing cytotoxic immune response in 
LP. This study included 33 skin biopsies from patients with 
LP and 10 control biopsies. MxA mRNA was detected by 
RT-PCR. HCV-specific antibodies were detected in patient 
sera by ELISA. Analysis revealed a significantly higher level 
of MxA protein in all the LP skin biopsies compared with 
controls. The expression was significantly higher in HCV-
positive patients than in HCV-negative patients. Type I IFNs 
probably play a major role in the pathogenesis of LP, and 
HCV could induce LP through increasing the production 
of type I IFNs. Br J Dermatol 2009; 160:980–3.
Imiquimod and lentigo maligna: a search for 
prognostic features in a clinicopathological 
study with long-term follow-up
Although surgical excision is the treatment of choice 
for lentigo maligna, this may not be desirable or fea-
sible for large lesions at functionally or cosmetically 
important sites. Forty-eight patients were treated with 
imiquimod. There were 37 responders and 11 treatment 
failures (of whom two were ‘partial responders’). Of 
the 37 responders, 31 showed a clinical inflammatory 
response to imiquimod. One patient in whom treatment 
failed subsequently developed invasive disease. The mean 
follow-up duration was 49 months. Histological features 
of prognostic significance could not be identified. 
However, the ability to develop an inflammatory reaction 
to imiquimod was a strong predictor of therapeutic 
benefit. Br J Dermatol 2009; 160:994–8.
Treatment of infraorbital dark circles  
by autologous fat transplantation: a pilot study
This study was conducted to clarify the nature of dark 
circles under the eyes and to determine the efficacy of 
autologous fat transplantation. Ten patients with dark cir-
cles due to increased vascularity and translucency of the 
skin were included. They received at least one autologous 
fat transplantation and follow-up evaluations were con-
ducted at least 3 months after the last treatment. A mean 
of 1.6 autologous fat transplantations was carried out in 
both infraorbital areas. Patients showed a mean of 78% 
improvement (mean grading scale: 2.6 out of 4). Most of 
the patients showed improvement in the infraorbital dark-
ening and contour of the lower eyelids. Br J Dermatol 
2009; 160:1022–5.
Epidemiology and clinical pattern of 
psoriatic arthritis in Germany: a prospective 
interdisciplinary epidemiological study  
of 1511 patients with plaque-type psoriasis
Reich et al. investigated the prevalence and clinical pattern 
of psoriatic arthritis (PsA) in a daily practice population of 
patients with psoriasis. Among 1511 patients 20.6% had 
PsA; in 85% of the cases PsA was newly diagnosed. Of these 
patients more than 95% had active arthritis and 53.0% had 
five or more joints affected. Polyarthritis (58.7%) was the 
most common manifestation pattern. Distal interphalangeal 
involvement was present in 41.0% of the patients. Compared 
with patients without arthritis, patients with PsA had more 
severe skin symptoms (mean PASI 14.3 vs. 11.5), a lower 
quality of life (mean DLQI 11.6 vs. 7.7) and greater impair-
ment of productivity parameters. The findings are consistent 
with a high prevalence of undiagnosed cases of active PsA 
among patients with psoriasis seen by dermatologists. Br J 
Dermatol 2009; 160:1040–7.
The Birmingham Epidermolysis Bullosa 
Severity score: development and validation
The purpose of this study was to develop a severity score 
covering all subtypes of epidermolysis bullosa (EB) at all 
ages that is simple, valid, sensitive and reliable. Score items 
and weightings were generated by expert consensus, and 
refined for content and face validity. The Birmingham EB 
Severity (BEBS) score was tested on 97 patients aged 0–64 
years. Eleven items were scored: area of damaged skin, 
involvement of nails, mouth, eyes, larynx and oesophagus, 
scarring of hands, skin cancer, chronic wounds, alopecia and 
nutritional compromise. Area was allocated 50 points, and 
the 10 other items 5 points each, giving a maximum score 
of 100. Lowest BEBS scores occurred in Weber–Cockayne 
EB simplex (median 1.0; range 0.1–3.0; n = 12), highest 
scores in generalized non-Herlitz junctional EB (28.5; 
5.0–62.0; n = 7), Hallopeau–Siemens recessive dystrophic 
EB (HS-RDEB) (22.9; 4.3–69.0; n = 23) and Herlitz 
junctional EB (H-JEB) (14.4; 2.5–49.3; n = 9), and inter-
mediate scores in dominant dystrophic EB (5.3; 0.5–15.9; 
n = 19), Dowling–Meara EB simplex (DM-EBS) (6.3; 
2.8–22.5; n = 16) and non-Hallopeau–Siemens recessive 
dystrophic EB (7.8, 2.8–27.8; n = 11). Intra- and interobserver 
correlations were high. With age, scores increased for H-JEB 
(r = 0.9, P = 0.001) and HS-RDEB (r = 0.73, P = 0.001) 
and decreased for DM-EBS (r = –0.62, P = 0.01), with posi-
tive but nonsignificant correlations for the other types. Br J 
Dermatol 2009; 160:1057–65.
